What is the Atopic Dermatitis Market Size?

on

 


 

DelveInsight's "Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Atopic Dermatitis, historical and forecasted epidemiology as well as the Atopic Dermatitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

The Atopic Dermatitis market size report provides current treatment practices, emerging drugs, Atopic Dermatitis market share of the individual therapies, current and forecasted Atopic Dermatitis market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Atopic Dermatitis treatment practice/algorithm, market drivers, market barriers and Atopic Dermatitis unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Atopic Dermatitis also called eczema is a chronic condition and the most common type of skin inflammation that usually starts in early childhood, but can occur at any age and can be recurrent or persistent throughout life. Half of the patients with moderate-to-severe eczema also have asthma, hay fever (allergic rhinitis), and food allergies. It is the most common chronic skin disease in children. 

Atopic Dermatitis presents different symptoms depending on the age of the person. Itching is the hallmark of Atopic Dermatitis. Sore or painful skin and poor sleep caused by itching are also common. People with Atopic Dermatitis may develop rashes anywhere on the body that can ooze, weep fluid and bleed when scratched, making skin vulnerable to infection. Skin can become dry and discolored, and repeated scratching may cause thickening and hardening of the skin (lichenification). 

The exact cause of Atopic Dermatitis is unknown. Atopic Dermatitis is caused by a complex interaction of immune dysregulation, epidermal gene mutations, and environmental factors that disrupt the epidermis causing intensely pruritic skin lesions. However, it is not contagious. There is currently no reliable biomarker that can distinguish the disease from other entities. However, the most commonly used biomarker is elevated total and/or allergen-specific serum IgE. 

For more information about the market report @ Atopic Dermatitis Market Outlook

Currently, the treatment regimen of Atopic Dermatitis involves the use of topical treatment options such as emollients, topical corticosteroids (TCS) topical calcineurin inhibitors (TCIs) and systemic treatment such as immunosuppressant, corticosteroids, and others (phototherapy). Additionally, certain systemic therapies like Dupixent, Rinvoq, Olumiant, Cibinqo, Opzelura and others are also approved for Atopic Dermatitis in the 7MM. 

Atopic Dermatitis market is expected to witness a significant growth rate owing to launch of potential mid and late stage therapies in the coming years, assisted by an increase in the prevalent population of Atopic Dermatitis.

What is the Atopic Dermatitis Market Forecast?

Drug chapter segment of the Atopic Dermatitis report encloses the detailed analysis of Atopic Dermatitis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Atopic Dermatitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. 

Atopic Dermatitis Marketed Drugs 

Dupixent (Sanofi/Regeneron Pharmaceuticals)

Dupixent is a fully-human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins and is not an immunosuppressant. Data from Dupixent clinical trials have shown that IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in Atopic Dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis (CRSwNP). In May 2020, the US FDA approved Dupixent (dupilumab) for children aged 6–11 years with moderate-to-severe Atopic Dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent is currently approved in more than 60 countries, and more than 190,000 patients have been treated globally. 

Eucrisa (Pfizer)

Eucrisa (crisaborole) is a non-steroidal phosphodiesterase-4 (PDE4) inhibitor indicated for the topical treatment of mild-to-moderate Atopic Dermatitis in patients 2 years of age and older. It is currently available as a 2% ointment. In March 2020, the US FDA approved Pfizer’s supplemental new drug application (sNDA) for Eucrisa (crisaborole) ointment, 2%, extending the lower age limit from 24 months down to 3 months in children with mild-to-moderate Atopic Dermatitis. The drug is a small, boron-based molecule with low molecular weight, which allows easier penetration into the skin. The EMA also approved Staquis (crisaborole) to treat adults and children from 2 years of age with mild to moderate Atopic Dermatitis, in March 2020. 

Corectim Ointment (Japan Tobacco and Torii Pharmaceutical)

Corectim (delgocitinib) Ointment 0.5% is a non-steroidal topical product and the world’s first topical JAK inhibitor that improves Atopic Dermatitis by inhibiting the action of all members of the JAK family [JAK1, JAK2, JAK3, and tyrosine kinase 2], which play a key role in immune activation signaling in cells, by suppressing the overactivation of immune responses. In October 2016, Japan Tobacco and Torii Pharmaceutical signed an exclusive agreement for co-development and commercialization of JT’s original compound, JTE-052 (delgocitinib), for topical use in dermatological indications in Japan. 

Olumiant (baricitinib) (Eli Lilly and Company)

Baricitinib (LY3009104) – discovered by Incyte and developed under license by Lilly and marketed as Olumiant – is an oral selective Janus kinase (JAK) 1/JAK2 inhibitor. It inhibits several cytokines in Atopic Dermatitis pathogenesis, including thymic stromal lymphopoietin, IL-4, IL-5, IL-13, IL-22, and IL-31. The drug works by blocking the action of enzymes known as JAK1/JAK2 inhibitor that mediate the pathways involved in the inflammatory process in Atopic Dermatitis. In addition, the drug is already approved in EU for the treatment of moderate and severe Atopic Dermatitis. It is the first medicine for moderate and severe Atopic Dermatitis that patients can be taken orally. It is also approved in over 40 countries for the treatment of adults with moderate to severe Atopic Dermatitis who are candidates for systemic therapy. Eli Lilly and partner Incyte have filed a regulatory review for JAK inhibitor Olumiant to treat Atopic Dermatitis in the US. 

Rinvoq (AbbVie)

Upadacitinib (ABT-494) – discovered and developed by AbbVie scientists and marketed as Rinvoq – is a selective and reversible JAK inhibitor that was approved by FDA and EMA in August 2019 and December 2019, respectively, for adult patients with moderately to severely active rheumatoid arthritis. JAKs are intracellular enzymes that transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Upadacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. The European Commission in August 2021 approved Rinvoq to treat adults (15 mg and 30 mg) and adolescents (15 mg) with Atopic Dermatitis. In January 2022, the US FDA approved Rinvoq for the treatment of moderate to severe Atopic Dermatitis in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including biologic medicines, or when use of other pills or injections is not recommended. 

Cibinqo (Pfizer)

Abrocitinib (PF-04965842) is an oral, small molecule that selectively inhibits Janus kinase (JAK) 1. Inhibition of JAK1 modulates multiple cytokines involved in the pathophysiology of Atopic Dermatitis, including interleukin (IL)-4, IL-13, IL-31, IL-22, and thymic stromal lymphopoietin (TSLP). Abrocitinib reversibly inhibits JAK1 by blocking the adenosine triphosphate (ATP) binding site. In January 2022, the US FDA approved Cibinqo for the treatment of adults living with refractory, moderate-to-severe Atopic Dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. In addition to receiving regulatory approval in the US, CIBINQO has received marketing authorization in the European Union, Great Britain, Japan, Korea, the United Arab Emirates, Norway, Iceland, and Singapore. 

Adbry/ Adtralza (LEO Pharma)

Tralokinumab (Adbry/ Adtralza) is a fully human monoclonal antibody that specifically neutralizes the IL-13 cytokine, a key driver of the underlying inflammation in Atopic Dermatitis, and inhibits its interaction with the IL-13 receptor α1 and α2 subunits (IL-13Rα1 and IL13Rα2). Adtralza has been approved by the European Commission for adults with moderate-to-severe Atopic Dermatitis in Europe and by the Medicines and Healthcare products Regulatory Agency in Great Britain, in June 2021. Additional regulatory filings are underway with other health authorities worldwide. In December 2021 the US FDA approved Adbry (tralokinumab-ldrm) for the treatment of moderate-to-severe Atopic Dermatitis in adults 18 years or older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. 

Opzelura (Incyte Corporation)

Opzelura (Ruxolitinib) is a potent, selective inhibitor of JAK1 and JAK2 that, when applied topically, provides the opportunity to directly target diverse pathogenic pathways that underlie Atopic Dermatitis. It is a prescription topical cream for the short-term, non-continuous treatment of mild to moderate eczema (atopic dermatitis) not controlled on topical therapies in people 12 and older without weakened immune systems. 

Atopic Dermatitis Emerging Drugs

Drug chapter segment of the Atopic Dermatitis report encloses the detailed analysis of Atopic Dermatitis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Atopic Dermatitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

 

Lebrikizumab (Eli Lilly and Company)

Lebrikizumab (Ly3650150, Drm06), a novel, investigational, monoclonal antibody, is designed to bind IL-13 with very high affinity to specifically prevent the formation of the IL-13Rα1/IL-4Rα heterodimer complex and subsequent signaling, thereby inhibiting the biological effects of IL-13 in a targeted and efficient fashion. IL-13 is believed to be a central pathogenic mediator that drives multiple aspects of the pathophysiology underlying the range of signs and symptoms of Atopic Dermatitis by promoting type II inflammation and mediating its effects on tissue, resulting in skin barrier dysfunction, itch, skin thickening, and infection. The FDA has granted Fast Track designation to lebrikizumab for moderate-to-severe Atopic Dermatitis in patients aged 12 years and older and 40 kg or greater. Eli Lilly has exclusive rights for the development and commercialization of lebrikizumab in the US and the rest of the world outside Europe. 

Etrasimod (Arena Pharmaceuticals)

Etrasimod (APD334) is a next-generation, once-daily, oral, highly selective sphingosine 1-phosphate (S1P) receptor modulator discovered by Arena and designed for optimized pharmacology and engagement of S1P receptor 1, 4, and 5 providing systemic and local effects on specific immune cell types. The drug has the potential to treat multiple immune-mediated inflammatory diseases, including ulcerative colitis, Crohn’s disease, Atopic Dermatitis, and alopecia areata. In November 2020, based on the compelling profile in the Atopic DermatitisVICE trial, the company mentioned that the drug would be proceeding further into a Phase III registration program. 

Roflumilast (Arcutis Biotherapeutics)

Topical Roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase type 4 (PDE4), an intracellular enzyme that increases the production of pro-inflammatory mediators and decreases the production of anti-inflammatory mediators. It has been implicated in a wide range of inflammatory diseases, including psoriasis, eczema, and chronic obstructive pulmonary disease (COPD). 

FB825 (Oneness Biotech)

FB825 is a humanized monoclonal antibody that binds to the CεmX domain of membrane form IgE, leading to the death of IgE+ B lymphocytes by inducing apoptosis and antibody-dependent cellular cytotoxicity (Atopic DermatitisCC). The drug has both therapeutic as well as preventive effects in allergic diseases. In April 2020, LEO Pharma signed a worldwide exclusive licensing agreement with Oneness Biotech (Taiwan) covering the development and commercialization of the novel Atopic Dermatitis drug candidate, FB825. Moreover, the company plans to proceed with primary efficacy analysis in Q4 2021. Furthermore, the data readout is anticipated in March 2022 and completion of the clinical study report is expected in Q2 2022. 

DS107 (DS Biopharma)

DS107 (DGLA, Daleuton) is a novel, immunomodulating, bioactive lipid that targets the immune activation and skin barrier dysfunction of Atopic Dermatitis by inhibiting the expression of CD40. Inhibition of CD40 in Atopic Dermatitis patients down regulates T-cell activation and downstream Th2, Th1, Th17, and Th22 cytokine production (DS Biopharma, 2018). The drug has completed Phase II clinical studies for moderate-to-severe Atopic Dermatitis in adults in both topical cream and oral formulations and is phase III ready. 

B244 (AOBiome Therapeutics)

AOBiome’s B244 is a patented, proprietary, topical formulation incorporating a single strain of beneficial ammonia-oxidizing bacteria (AOB), Nitrosomonas eutropha D23. B244 is designed to repopulate the skin microbiome with AOBs normally found on the body but frequently stripped away by most soaps. Once deployed on the skin, B244 converts ammonia to nitrite, known to have antibacterial properties, and to nitric oxide, a signaling molecule known to regulate inflammation and vasodilation. The drug is currently undergoing a phase II trial pruritus (itch) caused by Atopic Dermatitis (eczema) in adults ages 18–65 years in various locations.

Source:- Atopic Dermatitis Market Drugs

List of Top Selling Market Research Reports in 2023


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.


Contact Us

Yash Bhardwaj

info@delveinsight.com

Comments

Post a Comment